Xeris Biopharma(US:XERS)2025-07-03 13:51Financial Outlook & Growth Strategy - Xeris expects total revenue of approximately $260 million to $275 million in 2025 and to maintain positive adjusted EBITDA [21] - The company anticipates total revenue to reach approximately $750 million by 2030, driven by Recorlev and the launch of XP-8121 [20, 127] - Xeris projects Recorlev to achieve peak net revenue between $1 billion and $3 billion, with XP-8121 also expected to reach $1 billion to $3 billion in peak net revenue [23, 99, 132] Recorlev Growth Opportunities - Recorlev is expected to approach $1 billion in annual net revenue [26, 40] - The U S addressable market for hypercortisolism is estimated at 3 to 5 million patients [23] - Recorlev inhibits cortisol production at multiple points in the cortisol production pathway [32] XP-8121 Hypothyroidism Treatment - XP-8121 is designed to improve patient experience and clinical outcomes in hypothyroidism [91] - XP-8121 targets a U S addressable market of 3 to 5 million treated patients with inconsistent TSH levels [23, 100] - XP-8121 has a multi-billion dollar peak revenue potential [98] Operational & Commercial Strengths - Xeris has a management team with experience in promoting pharmaceutical products and expertise in market preparedness [114] - The company has in-house capabilities across rare, ultra-rare, and retail markets, with dedicated sales, patient support, and medical education [114] - Xeris' commercial model is designed to drive continuous rapid growth [115]